The discovery of the Janus kinase 2 (JAK2) V617F mutation in 2005 has modified the understanding of the molecular basis of Ph-MPN and resulted in a revision of the WHO diagnostic criteria[2-4]. The gene discussed is JAK2; the disease is myeloproliferative disorder.